We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Oscar Health vs. Molina: Which Healthcare Stock Is a Better Buy?
Read MoreHide Full Article
Key Takeaways
Oscar Health holds an edge over Molina with stronger growth prospects, a lower valuation and stock gains.
OSCR's membership surged 46% to 2.96 million, while second-quarter revenues jumped 70% to $4.88 billion.
MOH faces rising medical costs & enrollment challenges, while OSCR targets a 20% revenue CAGR through 2027.
The U.S. health insurance industry benefits from diversified, affordable plans that support stable premium revenues and contract retention. However, stricter Medicaid eligibility requirements and declining ACA enrollment could put pressure on membership growth and reimbursements. An aging population should sustain demand for Medicare products and support premium expansion. Meanwhile, investments in telehealth, AI, cloud computing and data analytics are improving operational efficiency and member engagement, despite upfront costs. Strategic acquisitions further strengthen market presence, diversify operations and create long-term growth opportunities.
In this backdrop, let’s assess which company is better positioned with sustainable long-term prospects: Oscar Health (OSCR - Free Report) or Molina Healthcare (MOH - Free Report) .
Oscar Health is a leading healthcare technology company built around a full-stack technology platform. It is well-positioned for sustained growth as it strengthens its presence in the expanding U.S. individual health insurance market.
Molina Healthcare is a multi-state managed care organization focused on government-sponsored healthcare programs. Molina Healthcare remains well positioned to capitalize on favorable government-sponsored healthcare trends, supported by its leading Medicaid franchise, growing Medicare Duals presence and a strong record of winning and retaining contracts.
The Case for OSCR
Structural changes in employment, including growing gig work, self-employment, part-time jobs and early retirement, are driving demand for health insurance beyond employer-sponsored coverage. Oscar Health is positioned to benefit from this trend through its technology-driven platform, which integrates plan design, member engagement, care navigation, claims processing and provider management. Its Individual Coverage Health Reimbursement Arrangements, Lucie Health marketplace and Trove Group further diversify growth opportunities.
Robust membership expansion underscores the increasing adoption of Oscar's offerings. Membership surged 46% year over year to 2.96 million as of June 30, 2026, while second-quarter revenues climbed 70% to $4.88 billion, supported by higher enrollment and premium rates. Management expects 2026 revenues between $18.7 billion and $19 billion, reflecting its expanding market presence.
Oscar plans to enter more than 150 additional metropolitan statistical areas by 2027, leveraging disciplined pricing, consumer-centric products and scalable technology to strengthen its ACA marketplace footprint. Rising healthcare costs, digitalization and growing demand for personalized insurance solutions provide additional long-term opportunities.
Management targets a 20% revenue CAGR through 2027 and a 5% operating margin in 2027. Technology investments, AI-driven efficiencies, operating leverage and declining risk-adjustment expenses relative to premiums should support margin improvement.
Oscar's strong liquidity further reinforces its growth prospects. As of June 30, 2026, the company held approximately $4.08 billion in cash and equivalents and $6.08 billion in investments, compared with $432 million in long-term debt, providing financial flexibility to fund expansion, technology investments and regulatory capital requirements.
The Case for MOH
Molina Healthcare is positioned to capitalize on long-term growth opportunities in government-sponsored healthcare, supported by an aging U.S. population, rising healthcare spending and increasing demand for Medicare Advantage and Dual-Eligible Special Needs Plans (D-SNPs). Its strategic focus on D-SNPs, backed by established Medicaid provider networks and care-management expertise, should strengthen its Medicare presence. Additionally, states' growing reliance on private insurers to administer Medicaid programs provides opportunities for membership and premium growth.
Molina's proven ability to secure and retain Medicaid managed-care contracts remains a key competitive strength. Its expertise in serving medically complex populations, disciplined pricing and strong operational capabilities support contract wins and long-term growth. Strategic acquisitions of small and mid-sized businesses further reinforce its government-sponsored healthcare portfolio.
However, elevated medical costs remain a significant concern, as Medicaid reimbursement rates often lag utilization trends and medical inflation. Higher outpatient and behavioral health spending, specialty drug costs and provider wage pressures continue to strain margins. Management reaffirmed Medicaid MCR guidance of 92.9% while raising Marketplace MCR expectations to 90% from 85.5%, reflecting unfavorable member acuity and risk-adjustment pressures.
Enrollment challenges and portfolio restructuring also pose headwinds. Molina plans to exit its unprofitable MAPD business in 2027, reduce Marketplace premiums by approximately $1 billion and absorb a $500 million revenue impact from California's Medicaid policy changes. Despite projected 2027 premium revenues of $46.5 billion, regulatory uncertainty, persistent cost pressures and execution risks could constrain profitability and growth.
Estimates for OSCR and MOH
The Zacks Consensus Estimate for OSCR’s 2026 and 2027 revenues implies a 60.8% and 10.3% year-over-year increase, respectively. EPS estimates for 2026 and 2027 imply a 208.3% and 21% year-over-year increase, respectively. EPS estimates for 2026 and 2027 witnessed 18.8% and 24% northbound movement, respectively, in the past 30 days. The expected long-term earnings growth rate is pegged at 49.7% and the company has a Growth Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MOH’s 2026 revenues implies a 2.1% decrease, whereas the same for 2027 suggests a 7.9% year-over-year increase. EPS estimates for 2026 and 2027 indicate a 52.1% decrease and an 84.7% year-over-year increase, respectively. EPS estimates for 2026 witnessed 1 cent southbound movement but those for 2027 witnessed no movement in the past 30 days. The expected long-term earnings growth rate is pegged at 1.7% and the company has a Growth Score of C.
Image Source: Zacks Investment Research
Price Performance of OSCR and MOH
OSCR shares have gained 132.9% year to date, while MOH shares have gained 22.5% in the same time.
Image Source: Zacks Investment Research
Are OSCR and MOH Shares Expensive?
OSCR is trading at a forward 12-month price-to-earnings multiple of 15.66, lower than its median of 20.58 over the past three years. MOH’s forward 12-month price-to-earnings multiple sits at 24.07, higher than its median of 13.37 over the past three years.
Image Source: Zacks Investment Research
Conclusion
Oscar’s expanding membership, improving cost structure, scalable technology platform, consistent underwriting discipline and solid balance sheet will help it convert its strong results into durable earnings.
Strong growth prospects, contract wins and acquisitions support premium stability, while disciplined medical cost management and efficiency efforts sustain liquidity and strategic flexibility for Molina.
OSCR sports a Zacks Rank #1 (Strong Buy) and has a VGM Score of A. MOH carries a Zacks Rank #4 (Sell), though it has a VGM Score of B. Oscar Health’s diversified market presence, price appreciation, affordable valuation and cash generation capability give it an edge over Molina.
View the Zacks #1 Rank List
Image: Bigstock
Oscar Health vs. Molina: Which Healthcare Stock Is a Better Buy?
Key Takeaways
The U.S. health insurance industry benefits from diversified, affordable plans that support stable premium revenues and contract retention. However, stricter Medicaid eligibility requirements and declining ACA enrollment could put pressure on membership growth and reimbursements. An aging population should sustain demand for Medicare products and support premium expansion. Meanwhile, investments in telehealth, AI, cloud computing and data analytics are improving operational efficiency and member engagement, despite upfront costs. Strategic acquisitions further strengthen market presence, diversify operations and create long-term growth opportunities.
In this backdrop, let’s assess which company is better positioned with sustainable long-term prospects: Oscar Health (OSCR - Free Report) or Molina Healthcare (MOH - Free Report) .
Oscar Health is a leading healthcare technology company built around a full-stack technology platform. It is well-positioned for sustained growth as it strengthens its presence in the expanding U.S. individual health insurance market.
Molina Healthcare is a multi-state managed care organization focused on government-sponsored healthcare programs. Molina Healthcare remains well positioned to capitalize on favorable government-sponsored healthcare trends, supported by its leading Medicaid franchise, growing Medicare Duals presence and a strong record of winning and retaining contracts.
The Case for OSCR
Structural changes in employment, including growing gig work, self-employment, part-time jobs and early retirement, are driving demand for health insurance beyond employer-sponsored coverage. Oscar Health is positioned to benefit from this trend through its technology-driven platform, which integrates plan design, member engagement, care navigation, claims processing and provider management. Its Individual Coverage Health Reimbursement Arrangements, Lucie Health marketplace and Trove Group further diversify growth opportunities.
Robust membership expansion underscores the increasing adoption of Oscar's offerings. Membership surged 46% year over year to 2.96 million as of June 30, 2026, while second-quarter revenues climbed 70% to $4.88 billion, supported by higher enrollment and premium rates. Management expects 2026 revenues between $18.7 billion and $19 billion, reflecting its expanding market presence.
Oscar plans to enter more than 150 additional metropolitan statistical areas by 2027, leveraging disciplined pricing, consumer-centric products and scalable technology to strengthen its ACA marketplace footprint. Rising healthcare costs, digitalization and growing demand for personalized insurance solutions provide additional long-term opportunities.
Management targets a 20% revenue CAGR through 2027 and a 5% operating margin in 2027. Technology investments, AI-driven efficiencies, operating leverage and declining risk-adjustment expenses relative to premiums should support margin improvement.
Oscar's strong liquidity further reinforces its growth prospects. As of June 30, 2026, the company held approximately $4.08 billion in cash and equivalents and $6.08 billion in investments, compared with $432 million in long-term debt, providing financial flexibility to fund expansion, technology investments and regulatory capital requirements.
The Case for MOH
Molina Healthcare is positioned to capitalize on long-term growth opportunities in government-sponsored healthcare, supported by an aging U.S. population, rising healthcare spending and increasing demand for Medicare Advantage and Dual-Eligible Special Needs Plans (D-SNPs). Its strategic focus on D-SNPs, backed by established Medicaid provider networks and care-management expertise, should strengthen its Medicare presence. Additionally, states' growing reliance on private insurers to administer Medicaid programs provides opportunities for membership and premium growth.
Molina's proven ability to secure and retain Medicaid managed-care contracts remains a key competitive strength. Its expertise in serving medically complex populations, disciplined pricing and strong operational capabilities support contract wins and long-term growth. Strategic acquisitions of small and mid-sized businesses further reinforce its government-sponsored healthcare portfolio.
However, elevated medical costs remain a significant concern, as Medicaid reimbursement rates often lag utilization trends and medical inflation. Higher outpatient and behavioral health spending, specialty drug costs and provider wage pressures continue to strain margins. Management reaffirmed Medicaid MCR guidance of 92.9% while raising Marketplace MCR expectations to 90% from 85.5%, reflecting unfavorable member acuity and risk-adjustment pressures.
Enrollment challenges and portfolio restructuring also pose headwinds. Molina plans to exit its unprofitable MAPD business in 2027, reduce Marketplace premiums by approximately $1 billion and absorb a $500 million revenue impact from California's Medicaid policy changes. Despite projected 2027 premium revenues of $46.5 billion, regulatory uncertainty, persistent cost pressures and execution risks could constrain profitability and growth.
Estimates for OSCR and MOH
The Zacks Consensus Estimate for OSCR’s 2026 and 2027 revenues implies a 60.8% and 10.3% year-over-year increase, respectively. EPS estimates for 2026 and 2027 imply a 208.3% and 21% year-over-year increase, respectively. EPS estimates for 2026 and 2027 witnessed 18.8% and 24% northbound movement, respectively, in the past 30 days. The expected long-term earnings growth rate is pegged at 49.7% and the company has a Growth Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MOH’s 2026 revenues implies a 2.1% decrease, whereas the same for 2027 suggests a 7.9% year-over-year increase. EPS estimates for 2026 and 2027 indicate a 52.1% decrease and an 84.7% year-over-year increase, respectively. EPS estimates for 2026 witnessed 1 cent southbound movement but those for 2027 witnessed no movement in the past 30 days. The expected long-term earnings growth rate is pegged at 1.7% and the company has a Growth Score of C.
Image Source: Zacks Investment Research
Price Performance of OSCR and MOH
OSCR shares have gained 132.9% year to date, while MOH shares have gained 22.5% in the same time.
Image Source: Zacks Investment Research
Are OSCR and MOH Shares Expensive?
OSCR is trading at a forward 12-month price-to-earnings multiple of 15.66, lower than its median of 20.58 over the past three years. MOH’s forward 12-month price-to-earnings multiple sits at 24.07, higher than its median of 13.37 over the past three years.
Image Source: Zacks Investment Research
Conclusion
Oscar’s expanding membership, improving cost structure, scalable technology platform, consistent underwriting discipline and solid balance sheet will help it convert its strong results into durable earnings.
Strong growth prospects, contract wins and acquisitions support premium stability, while disciplined medical cost management and efficiency efforts sustain liquidity and strategic flexibility for Molina.
OSCR sports a Zacks Rank #1 (Strong Buy) and has a VGM Score of A. MOH carries a Zacks Rank #4 (Sell), though it has a VGM Score of B. Oscar Health’s diversified market presence, price appreciation, affordable valuation and cash generation capability give it an edge over Molina.
You can see the complete list of today’s Zacks #1 Rank stocks here.